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Abbreviations: 
AMD, age-related macular degeneration; ANOVA, analysis of variance; AP-1, activator 
protein 1; APE1, apurinic/apyrimidinic endonuclease 1; APX2009, (E)-N,N-diethyl-2-((3-
methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methylene)pentanamide; APX2014, (E)-
N-methoxy-2-((3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)methylene)pentanamide; APX3330, (2E)-2-[(4,5- dimethoxy-2-methyl-3,6-dioxo-1,4-
cyclohexadien-1-yl)methylene]-undecanoic acid; ATCC, American Type Culture 
Collection; BSA, bovine serum albumin; CNV, choroidal neovascularization; DAPI, 4ʹ,6-
diamidine-2ʹ-phenylindole; DMEM, Dulbecco’s modified Eagle’s medium; DMSO, 
dimethyl sulfoxide; EBM-2, endothelial basal medium 2; EdU, 5-ethynyl-2ʹ-deoxyuridine; 
EGM-2, endothelial growth medium 2; EMSA, electrophoretic mobility shift assay; FDA, 
Food and Drug Administration; FA, fluorescein angiography; GCL, ganglion cell layer; 
GI50, median growth inhibitory concentration; GS-IB4, isolectin B4 from Griffonia 
simplicifolia; HIF-1α, hypoxia inducible factor 1α; HRECs, human retinal microvascular 
endothelial cells; INL, inner nuclear layer; L-CNV, laser-induced choroidal 
neovascularization; NF-κB, nuclear factor κ light-chain-enhancer of activated B cells; 
OCT, optical coherence tomography; ONL, outer nuclear layer; PBS, phosphate 
buffered saline; PDR, proliferative diabetic retinopathy; PKT, propylene glycol, Kolliphor 
HS15, Tween 80; Ref-1, reduction-oxidation factor 1; qRT-PCR, quantitative reverse 
transcription-polymerase chain reaction; ROP, retinopathy of prematurity; RP2D, 
recommended Phase II dose; RPE, retinal pigment epithelium; STAT3, signal 
transducer and activator of transcription 3; TUNEL, terminal deoxynucleotidyl 
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transferase dUTP nick end labeling; VEGF, vascular endothelial growth factor; VLDLR, 
very low density lipoprotein receptor 
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Abstract 
Ocular neovascular diseases like wet age-related macular degeneration are a major 
cause of blindness. Novel therapies are greatly needed for these diseases. One 
appealing antiangiogenic target is reduction-oxidation factor 1-apurinic/apyrimidinic 
endonuclease 1 (Ref-1/APE1). This protein can act as a redox-sensitive transcriptional 
activator for NF-κB and other pro-angiogenic transcription factors. An existing inhibitor 
of Ref-1’s function, APX3330, previously showed antiangiogenic effects. Here, we 
developed improved APX3330 derivatives and assessed their antiangiogenic activity. 
We synthesized APX2009 and APX2014 and demonstrated enhanced inhibition of Ref-
1 function in a DNA-binding assay compared to APX3330. Both compounds were 
antiproliferative against human retinal microvascular endothelial cells (HRECs; GI50 
APX2009: 1.1 µM, APX2014: 110 nM) and macaque choroidal endothelial cells (Rf/6a  
GI50 APX2009: 26 µM, APX2014: 5.0 µM). Both compounds significantly reduced the 
ability of HRECs and Rf/6a cells to form tubes at mid nanomolar concentrations 
compared to control, and both significantly inhibited HREC and Rf/6a cell migration in a 
scratch wound assay, reducing NF-κB activation and downstream targets. Ex vivo, both 
APX2009 and APX2014 inhibited choroidal sprouting at low micromolar and high 
nanomolar concentrations respectively. In the laser-induced choroidal 
neovascularization mouse model, intraperitoneal APX2009 treatment significantly 
decreased lesion volume by 4-fold compared to vehicle (p < 0.0001, ANOVA with 
Dunnett’s post hoc tests), without obvious intraocular or systemic toxicity. Thus, Ref-1 
inhibition with APX2009 and APX2014 blocks ocular angiogenesis in vitro and ex vivo, 
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and APX2009 is an effective systemic therapy for CNV in vivo, establishing Ref-1 
inhibition as a promising therapeutic approach for ocular neovascularization.  
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Introduction 
Ocular neovascularization is the key pathobiological feature of diseases like 
proliferative diabetic retinopathy (PDR), retinopathy of prematurity (ROP), and wet age-
related macular degeneration (AMD), which together are major causes of blindness 
(Campochiaro, 2013). In PDR and ROP, abnormal blood vessels grow in and on the 
retina, while in wet AMD, neovessels grow from the pigmented, subretinal choroid layer 
into the retina. In all cases, neovessels disrupt retinal architecture and can hemorrhage, 
leading to blindness. Although the exact stimuli promoting neovascularization are not 
always well characterized, hypoxia and inflammation both play crucial roles. The 
currently used, FDA approved pharmacological treatments for these diseases are all 
biologics targeting the vascular endothelial growth factor (VEGF) signaling pathway, 
such as ranibizumab and aflibercept (Prasad et al., 2010). Although these therapeutic 
agents have been very successful, significant proportions of patients are resistant and 
refractory (Lux et al., 2007; Falavarjani and Nguyen, 2013). Moreover, serious side 
effects including hemorrhage and endophthalmitis are possible. Therefore, development 
of novel therapeutic approaches targeting other signaling pathways is crucial. 
One such potential target is the reduction-oxidation factor 1-apurinic/apyrimidinic 
endonuclease 1 (Ref-1/APE1), an intracellular signaling nexus with important roles in 
transducing proangiogenic stimuli. This bifunctional protein has an endonuclease role 
essential for base excision repair (APE1), while the Ref-1 activity is a redox-sensitive 
transcriptional activator (Shah et al., 2017). Ref-1 redox signaling is a highly regulated 
process that reduces oxidized cysteine residues in specific transcription factors as part 
of their transactivation (Xanthoudakis and Curran, 1992; Xanthoudakis et al., 1992; 
.CC-BY 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/296590doi: bioRxiv preprint first posted online Apr. 6, 2018; 
  7 
Evans et al., 2000; Lando et al., 2000; Nishi et al., 2002; Seo et al., 2002; Li et al., 2010; 
Fishel et al., 2011; Cardoso et al., 2012; Kelley et al., 2012; Luo et al., 2012; Zhang et 
al., 2013; Fishel et al., 2015; Logsdon et al., 2016). This redox signaling affects 
numerous transcription factors including HIF-1α, NF-κB, and others. The regulation of 
HIF-1α and NF-κB are particularly relevant to angiogenesis and eye diseases (Evans et 
al., 2000; Nishi et al., 2002; Seo et al., 2002; Fishel et al., 2011; Cardoso et al., 2012; 
Fishel et al., 2015; Logsdon et al., 2016).  
Excitingly, Ref-1 activity can be targeted pharmacologically. APX3330 (formerly 
called E3330) is a specific Ref-1/APE1 redox inhibitor. APX3330 has been extensively 
characterized as a direct, highly selective inhibitor of Ref-1 redox activity that does not 
affect the protein’s endonuclease activity (Luo et al., 2008; Fishel et al., 2010; Su et al., 
2011; Cardoso et al., 2012; Luo et al., 2012; Zhang et al., 2013; Fishel et al., 2015). 
Pharmacologic inhibition of Ref-1 via APX3330 blocks Ref-1 redox activity on NF-κB, 
HIF-1α, AP-1, and STAT3, decreasing transcription factor binding to DNA in vitro (Fishel 
et al., 2011; Jedinak et al., 2011; Luo et al., 2012). APX3330 has entered Phase I 
clinical trials for safety and recommended Phase II dose (RP2D) in cancer patients 
(NCT03375086); however, the safety and dose administration of APX3330 have been 
previously established by Eisai Inc. through a prior development program for a non-
cancer, Hepatitis C indication that evaluated the preclinical toxicology, Phase I and 
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Phase II safety and clinical profile in more than 400 non-cancer patients (Shah et al., 
2017).  
Ref-1/APE1 is highly expressed during retinal development, and in retinal 
pigment epithelium (RPE) cells, pericytes, choroidal endothelial cells and retinal 
endothelial cells (Chiarini et al., 2000; Jiang et al., 2011; Li et al., 2014a). More 
generally, Ref-1 is frequently upregulated in regions of tissues in which inflammation is 
present (Zou et al., 2009; Kelley et al., 2010). APX3330 was previously shown to block 
in vitro angiogenesis, as evidenced by proliferation, migration, and tube formation of 
retinal and choroidal endothelial cells (Jiang et al., 2011; Li et al., 2014b). Indeed, 
APX3330 delivered intravitreally (directly into the eye) reduced neovascularization in the 
very low density lipoprotein receptor (VLDLR) knockout mouse model of retinal 
neovascularization (Jiang et al., 2011), and also in laser-induced choroidal 
neovascularization (L-CNV) (Li et al., 2014b), the most widely used animal model that 
recapitulates features of wet AMD (Grossniklaus et al., 2010).  
While the lead clinical candidate is effective in preclinical cancer studies, we also 
sought novel, second generation Ref-1 inhibitors that would have increased efficacy in 
antiangiogenic and anti-inflammatory transcription factor (NF-κB, HIF-1α) inhibition, as 
well as new chemical properties. We present here the synthesis of APX3330 derivatives 
APX2009 (reported previously as a neuroprotective agent (Kelley et al., 2016)), and 
APX2014 (reported here for the first time (Kelley and Wikel, 2015)). We go on to show 
that these compounds have antiangiogenic activity against retinal and choroidal 
endothelial cells both in culture and in an ex vivo choroidal sprouting model. Finally, we 
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show that APX2009 is an effective systemic treatment for L-CNV, establishing these 
compounds as leads for further development for neovascular eye diseases.  
Materials and Methods 
Synthetic Methods. The compounds were synthesized by Cascade Custom 
Chemistry (Eugene, OR) and provided by Apexian Pharmaceuticals. In summary (Fig. 
1A), the common intermediate iodolawsone (2-iodo-3-hydroxy-1,4-naphthoquinone (1); 
available from Cascade Custom Chemistry) was treated with 2-propylacrylic acid (2), 
with oxalyl chloride and the corresponding amine, and with sodium methoxide in 
methanol to yield (E)-N,N-diethyl-2-((3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)methylene)pentanamide (6a; APX2009), and (E)-N-methoxy-2-((3-methoxy-1,4-dioxo-
1,4-dihydronaphthalen-2-yl)methylene)pentanamide (6b; APX2014). Full synthetic 
details can be found in the Supplemental Methods. APX3330 was synthesized as 
described (Luo et al., 2008). 
Electrophoretic mobility shift assays (EMSA). These assays were performed 
as previously described (Luo et al., 2008; Kelley et al., 2011; Su et al., 2011; Luo et al., 
2012; Zhang et al., 2013). Briefly, an increasing amount of APX3330, APX2009 or 
APX2014 was preincubated with purified Ref-1 protein in EMSA reaction buffer for 30 
min. The EMSA assay was performed using the AP-1 target DNA sequence and AP-1 
protein. 
Cells. Primary human retinal microvascular endothelial cells (HRECs) were 
obtained from Cell Systems, Inc. (Kirkland, WA), while the Rf/6a macacque choroidal 
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endothelial cell line was obtained from ATCC (Manassas, VA). Cells were maintained 
as described (Basavarajappa et al., 2017), re-ordered at least annually, and regularly 
assessed for mycoplasma contamination.  
In vitro cell proliferation assay. Endothelial cell proliferation was assessed as 
described previously (Basavarajappa et al., 2014; Basavarajappa et al., 2017). Briefly, 
2.5×103 cells were seeded in 100 μL of growth medium and plated in each well of 96-
well clear-bottom black plates and incubated for 24 h. APX2009, APX2014, or DMSO 
vehicle (DMSO final concentration = 1%) was added, and the plates were incubated for 
24–48 h at 37°C and 5% CO2. AlamarBlue reagent (11.1 μL) was added to each well of 
the plate and 4 h later fluorescence readings were taken at excitation and emission 
wavelengths of 560 nm and 590 nm, respectively, using a Synergy H1 plate reader 
(BioTek, Winooski, VT). GI50 was calculated using GraphPad Prism v. 7.0. 
EdU incorporation, Ki-67 Staining, and TUNEL. These assays were carried 
out as described previously (Basavarajappa et al., 2014; Basavarajappa et al., 2017) 
but using chamber slides not coverslips. Briefly, cells (30,000 per well) were seeded on 
8-well chamber slides coated with attachment factors and allowed to attach overnight.  
Cells were treated with the indicated compound concentrations for 17 hours (overnight). 
To assay proliferation, cells were incubated with EdU in complete media for 8 hours at 
37°C.  Cells were then fixed in 4% paraformaldehyde for 20 min and permeabilized 
using 0.25% Triton X-100 prepared in PBS. Cells were incubated with a rabbit-specific 
monoclonal antibody against Ki-67 (D3B5) (#9129; Cell Signaling, Danvers, MA) (1:400) 
overnight at 4°C.  Secondary antibody was Alexa Fluor goat anti-rabbit 488 (A11034; 
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Invitrogen, Carlsbad, CA) with DAPI counter-stain for nuclear staining. Proliferating cells 
that incorporated EdU were detected using the Click-iT EdU Imaging kit (Invitrogen, 
Carlsbad, CA).  Alternatively, apoptotic cells were visualized using the Click-iT TUNEL 
assay kit (Invitrogen, Carlsbad, CA) as per the manufacturer's instructions, with Hoechst 
33342 counter-stain for nuclear staining, and a 17-hour treatment with 1 µM 
staurosporine as positive control. The cells were imaged using a Zeiss AxioImager D2 
microscope or an LSM 700 confocal microscope and the percentage of positive cells 
was counted on three low-power (for TUNEL) or high-power (for Ki-67 and EdU) fields 
per well using ImageJ software. 
Cell cycle analysis. HRECs (2´106) were grown in EGM-2 medium. Cells were 
serum starved in EBM-2 medium overnight, then treated with the indicated 
concentrations of APX2009 or APX2014 along with DMSO control for 24 hours in 
complete medium. Cells were washed twice in ice-cold PBS followed by fixation in 66% 
ethanol solution overnight at 4°C. Fixed cells were again washed twice in ice-cold PBS 
and the pellets were resuspended in propidium iodide staining solution for 30 mins at 
37°C (20 µg/mL propidium iodide prepared in 1´ PBS containing 0.1% Triton X-100 and 
100 µg/mL RNase A). After incubation cells were analyzed using flow cytometry 
(FACSCalibur, BD Biosciences, San Jose, CA). Pulse shape analysis was used to 
exclude doublets and debris. The single cell population was then assessed by the FL2 
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area histogram plot using ModFit software (v. 5.0) and cell cycle profiles were 
generated. 
In vitro cell migration assay. Endothelial cell migration was monitored as 
described before (Basavarajappa et al., 2014; Basavarajappa et al., 2017). Briefly, 
HRECs and Rf/6a were grown until confluency in 12-well plates. Using a sterile 10-μL 
micropipette tip, a scratch wound was made across the center of each well and fresh 
complete media containing DMSO or different concentrations of APX2009 or APX2014 
compounds were added to the wells (DMSO final concentration = 1%). Wells were 
imaged via digital brightfield microscopy at different time points, and the number of 
migrated cells into the scratched area was manually counted. 
In vitro Matrigel tube formation assay. The ability of HRECs and Rf/6a cells to 
form tubes in vitro was monitored as described before (Basavarajappa et al., 2014; 
Basavarajappa et al., 2017). Briefly, 1.5×104 cells in 100 μL of growth medium 
containing DMSO or APX compounds were added to each well of a 96-well plate that 
was pre-coated with 50 μL per well of Matrigel basement membrane (DMSO final 
concentration = 1%). Brightfield digital micrographs of each well at different time points 
were taken to measure the in vitro tube formation using the Angiogenesis Analyzer 
plugin in ImageJ software 
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(v.1.48; http://image.bio.methods.free.fr/ImageJ/?Angiogenesis-Analyzer-for-
ImageJ.html). 
NF-κB p65 nuclear translocation assay. The NF-κB nuclear translocation 
assay was performed by seeding 30,000 HRECs/well on an 8-well chamber slide 
coated with attachment factors. The cells were grown in EGM-2 medium overnight 
before treating with indicated concentrations of APX2009 and APX2014, or 10 µM BAY 
11-7082 (Sigma, St. Louis, MO) as a positive control NF-κB inhibitor. After 17 h 
incubation, the media was replaced with EBM-2 (minimal medium) with indicated 
concentrations of compound or DMSO for 1 hour. The cells were then stimulated with 
10 ng/ml TNF-α in EBM-2 for 20 min at 37°C to activate NF-κB. Cells were then fixed in 
4% paraformaldehyde and permeabilized using 0.5% Triton X-100 solution prepared in 
PBS. The cells were incubated with a monoclonal antibody against NF-κB p65 (sc-8008; 
Santa Cruz, Santa Cruz, CA) (1:50) overnight at 4°C, followed by Alexafluor 555 goat 
anti-mouse secondary antibody (1:2000) for one hour. The cells were counter-stained 
with Hoechst 33342 for nuclear staining and then mounted using Everbrite hardset 
mounting medium. The cells were imaged using a Zeiss AxioImager D2 microscope. 
qRT-PCR. The assay was performed as described previously (Basavarajappa et 
al., 2014; Basavarajappa et al., 2017). RNA was extracted from cells treated as 
indicated using Trizol (Invitrogen). cDNA was synthesized from 1 µg RNA using random 
primers and iScript reverse transcriptase (Bio-Rad, Hercules, CA). qPCR was 
performed in 10 μL volumes in a 384-well plate, with Fast Advanced Master Mix and 
TaqMan probes on a ViiA7 thermal cycler (Applied Biosystems, Foster City, CA). 
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Primer/probesets used were as follows: VEGFA (Hs00900055_m1), VCAM1 
(Hs01003372_m1), and CCL20 (Hs01011368_m1), and housekeeping controls 
HPRT (Hs02800695_m1) and TBP (Hs00427620_m1). The data were analyzed using 
the ΔΔCt method. The expression levels of genes were normalized to the two 
housekeeping genes and calibrated to the DMSO treated sample. 
Animals. All animal experiments were approved by the Indiana University School 
of Medicine Institutional Animal Care and Use Committee and followed the guidelines of 
the Association for Research in Vision and Ophthalmology Statement for the Use of 
Animals in Ophthalmic and Visual Research. Wild-type female C57BL/6 mice, 6–8 
weeks of age, were purchased from Envigo (Indianapolis, IN; for choroidal sprouting 
experiments) or Jackson Laboratory (Bar Harbor, ME; for L-CNV) and housed under 
standard conditions (Wenzel et al., 2015). Mice were anesthetized for all procedures by 
intraperitoneal injections of 90 mg/kg ketamine hydrochloride and 5 mg/kg xylazine, with 
intraperitoneal atipamezole reversal (1 mg/kg). Treatments were randomly assigned by 
cage.  
Choroidal sprouting assay. Ex vivo Choroidal sprouting was assessed as 
described previsouly (Sulaiman et al., 2016; Basavarajappa et al., 2017). Briefly, 
choroid–sclera was dissected from 7 to 8 week old mouse eyes and pieces were 
embedded in Matrigel (growth factor reduced) and grown in EGM-2 medium containing 
antibiotics for 72 h to allow sprouting to initiate. The indicated concentrations of 
APX2009 and APX2014 compounds (in DMSO, final DMSO concentration 0.5 and 
0.2%, respectively) were added and growth allowed to proceed for 48 h. Images were 
.CC-BY 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/296590doi: bioRxiv preprint first posted online Apr. 6, 2018; 
  15 
taken and growth was quantified by measuring the distance from the edge of the 
choroidal piece to the growth front in four directions per sample using ImageJ software. 
Laser-induced choroidal neovascularization. L-CNV was induced as 
described previously (Sulaiman et al., 2015; Sulaiman et al., 2016; Basavarajappa et 
al., 2017). Studies were powered to have an 80% chance of detecting effect size 
differences of 50%, assuming 30% variability, α = 0.05. Briefly, pupils of anesthetized 
mice were dilated with 1% tropicamide (Alcon Laboratories Inc., Forth Worth, TX) and 
lubricated with hypromellose ophthalmic demulcent solution (Gonak) (Akorn, Lake 
Forest, IL). A coverslip was used to allow viewing of the posterior pole of the eye. Three 
burns of a 532 nm ophthalmic argon green laser coupled with a slit lamp (50 μm spot 
size, 50 ms duration, and 250 mW pulses) were delivered to each 3, 9, and 12 o’clock 
position, two-disc diameters from optic disc. The bubbling or pop sensed after laser 
photocoagulation was considered as the successful rupture of Bruch’s membrane. 
Lesions in which bubbles were not observed were excluded from the study. To assess 
the antiangiogenic activity of APX3330, the mice were i.p. injected with compound (50 
mg/kg body weight), twice daily, five days on/two days off, as used previously in vivo 
(Fishel et al., 2011; Lou et al., 2014; Biswas et al., 2015). Vehicle was 4% 
Cremophor:ethanol (1:1) in PBS. For APX2009, doses were 12.5 mg/kg or 25 mg/kg 
body weight, twice daily until 14 days of laser treatment unless otherwise indicated. 
Vehicle was propylene glycol, Kolliphor HS15, Tween 80 (PKT) (McIlwain et al., 2018). 
Mice were weighed daily. 
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In vivo imaging. Optical coherence tomography (OCT) was performed in L-
CNV mice as described previously (Sulaiman et al., 2016), at the indicated times 
using the Micron III intraocular imaging system (Phoenix Research Labs, Pleasanton, 
CA). Briefly, before the procedure, eyes of anesthetized mice were dilated with 1% 
tropicamide solution (Alcon, Fort Worth, TX) and lubricated with hypromellose 
ophthalmic demulcent solution (Gonak) (Akorn, Lake Forest, IL, USA). Mice were 
then placed on a custom heated stage that moves freely to position the mouse eye 
for imaging. Several horizontal and vertical OCT images were taken per lesion. 
Fluorescein angiography was performed 14 days post laser by intraperitoneal 
injection of 50 μL of 25% fluorescein sodium (Fisher Scientific, Pittsburgh, PA). 
Fundus images were taken using the Micron III system and Streampix software.  
Choroidal flatmount immunofluorescence. Mouse eyes were harvested 14 
days after L-CNV induction. The eyes were enucleated and fixed in 4% 
paraformaldehyde/PBS overnight. The anterior segment, lens, and retina were 
removed, and the posterior eye cups were prepared for choroidal flat mounts. The 
posterior eye cups were washed with PBS and permeabilized in blocking buffer 
containing 0.3% Triton X-100, 5% bovine serum albumin (BSA) in PBS for two hours at 
4°C.  The eye cups were then double stained for vasculature with rhodamine-
labeled Ricinus communis agglutinin I (Vector Labs, Burlingame, CA) and Alexa FluorTM 
488 conjugated-Isolectin B4 from Griffonia simplicifolia (GS-IB4) (Molecular Probes, 
Thermo Fisher Scientific) at 1:250 dilution in buffer containing 0.3% Triton X-100, 0.5% 
BSA in PBS for 16–20 hours at 4°C. After antibody incubation, whole mounts were 
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washed three times with PBS for 15 mins each step at 4°C with 0.1% Triton X-100. After 
washing, choroidal flatmounts were mounted in aqueous mounting medium 
(VectaShield; Vector Laboratories, Inc.) and coverslipped for observation by confocal Z-
stack imaging (LSM 700, Zeiss, Thornwood, NY) to estimate lesion volume. The sum of 
the stained area in each optical section, multiplied by the distance between sections 
(3 μm), gave the CNV lesion volume and lesion volume was quantified using ImageJ 
software. Lesions were only included for analysis if they met quality control standards 
as published (Poor et al., 2014). All lesions in an eye were averaged to represent a 
single n.  
Statistical analyses. Statistical analyses were performed with GraphPad Prism 
7 software. One-way ANOVA was used with Dunnett’s post hoc test for EdU, Ki-67, 
TUNEL, cell cycle, migration, tube formation, qPCR, and choroidal sprouting 
experiments. Unpaired Student’s t-test was used for the APX3330 in vivo experiment. 
One-way ANOVA was used with Tukey’s post hoc test for L-CNV analysis in APX2009 
in vivo experiments, while repeated measures two-way ANOVA was used to compare 
body weights between treatments and over time. Two-sided p values < 0.05 were 
considered statistically significant.  
Results 
Novel Ref-1 inhibitors are more potent than APX3330 in blocking binding of 
AP-1 DNA binding. We synthesized APX2009 (6a) and APX2014 (6b) (Fig. 1A) and 
demonstrated that both compounds had enhanced inhibition of Ref-1-induced 
transcription factor binding to DNA compared to APX3330 (7) (Fig. 1B), while having 
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substantially different physiochemical properties. The new compounds have lower 
molecular weights, and lack the carboxylate group and long alkyl chain of APX3330. 
The new compounds also have significantly reduced lipophilicity as determined by 
computer based calculation of their clogP values, APX3330 = 4.5, APX2009 = 2.7, and 
APX2014 = 1.9. 
APX2009 and APX2014 block endothelial cell proliferation. Endothelial cell 
proliferation with increased survival supports the cells that make up new blood vessels, 
leading to angiogenesis. As an initial test of the antiangiogenic potential of our novel 
Ref-1 inhibitors, we assessed their ability to inhibit the proliferation of HRECs and Rf/6a 
choroidal endothelial cells (Fig. 2). Both compounds dose-dependently blocked 
proliferation of both cell types in an alamarBlue assay, with APX2014 5- to 10-fold more 
potent than APX2009. Primary HRECs were more sensitive to both compounds than the 
Rf/6a choroidal cell line, as seen with other antiangiogenic compounds (Basavarajappa 
et al., 2017). 
APX2009 and APX2014 block S phase without inducing apoptosis. We 
assessed the activity of our novel compounds in more detail in HRECs. Both 
compounds reduced the number of cells going through S phase as evidenced by 
reduced Ki-67 staining and reduced EdU incorporation (Fig. 3; Supplemental Figs. 1A & 
2). This was also evident as a modest increase in cells in G0/G1 phase at high doses of 
compound, with a concomitant decrease in G2/M phase cells (Supplemental Fig. 1B, C). 
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However, neither compound induced apoptosis at anti-proliferative doses as assessed 
by TUNEL (Supplemental Fig. 3). 
APX2009 and APX2014 block endothelial cell migration. Neovascularization 
involves an array of coordinated events, including extracellular matrix degradation, cell 
migration, cell proliferation, and morphogenesis of endothelial cells. To know the effect 
of APX2009 and APX2014 compounds on endothelial cell migration, a scratch-wound 
assay was performed. (Fig. 4; Supplemental Figs. 4 & 5). Both compounds again were 
dose-dependently and significantly effective here, without causing obvious cytotoxicity 
over the short time course of these assays. 
APX2009 and APX2014 block endothelial cell tube formation. Endothelial 
cells organize and form capillary-like structures upon plating on an extracellular matrix 
such as Matrigel. The organization of endothelial cells into a three-dimensional network 
of tubes is essential for angiogenesis. As such, the Matrigel tube formation assay is a 
good in vitro predictor of angiogenic potential in vivo. In this assay, both APX2009 and 
APX2014 inhibited tubule formation markedly, at concentrations lower than those 
required for inhibiting migration alone, strongly indicative of antiangiogenic activity (Fig. 
5; Supplemental Figs. 6 & 7). 
APX2009 and APX2014 inhibit NF-κB activity. Since Ref-1 inhibition has 
previously been associated with reduction in NF-κB activity (Shah et al., 2017), we 
assessed activity of this pathway in response to our novel compounds in HRECs, to 
determine if APX2009 and APX2014 were acting through the expected mechanisms. 
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First, we assayed translocation of the p65 subunit of NF-κB into the nucleus in response 
to TNF-α, a key indication of pathway activity. Translocation of p65 was dose-
dependently attenuated in APX2009 and APX2014-treated HRECs (Fig. 6A). Moreover, 
production of the mRNA of VEGFA, VCAM1, and CCL20, all of which are downstream 
of NF-κB, was decreased 3- to 10-fold by these compounds (Fig. 6B, C, D). 
APX2009 and APX2014 block angiogenesis ex vivo. As a further test of 
antiangiogenic activity, we employed a choroidal sprouting assay using murine 
choroidal explants to test the effect of the APX compounds in a complex microvascular 
bed in tissues (Fig. 7). In this assay, choroidal cells grow out of the choroidal tissue 
piece into a surrounding Matrigel matrix. Both compounds significantly reduced 
sprouting, with APX2014 remaining more potent. At 10 µM, APX2009 reduced sprouting 
by ~70% compared to control (Fig. 7A, B), while at 1 µM (the highest concentration 
tested), APX2014 reduced sprouting by ~60% compared to control (Fig. 7C, D). 
Systemic Ref-1 inhibition with parent compound APX3330 can prevent L-
CNV. Previous efforts to attenuate ocular neovascularization by Ref-1 inhibition using 
APX3330 relied on intravitreal delivery of compound (Jiang et al., 2011; Li et al., 2014a; 
Li et al., 2014b). Although this is the delivery route of the standard-of-care anti-VEGF 
biologics and ensures that the drug gets to the right place, in humans it is labor-
intensive, causes patient discomfort, and incurs a risk of potentially vision-threatening 
endophthalmitis (Day et al., 2011). Thus, we explored if systemic (intraperitoneal) 
administration of Ref-1 inhibitors could offer an alternative route of therapy for L-CNV. 
As a proof-of-concept, we tested i.p. injections of the first-generation Ref-1 inhibitor 
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APX3330 (7) delivered 50 mg/kg twice daily, 5 days on/two days off, for two weeks. This 
dosing regimen was chosen as it was previously successful and non-toxic for preclinical 
tumor studies (Fishel et al., 2011; Lou et al., 2014; Biswas et al., 2015). Animals treated 
with APX3330 displayed significantly reduced L-CNV volume (Fig. 8). 
Systemic administration of more potent derivative APX2009 reduces L-CNV 
significantly. Given that APX3330 reduced L-CNV with systemic adminstration, we 
explored if similar effects could be observed with our second-generation Ref-1 
inhibitors. We chose APX2009 for this experiment as it had previously been safely 
dosed in animals (Kelley et al., 2016). We used two dosage regimens previously 
employed, 12.5 or 25 mg/kg twice daily for two weeks. The lower dose did not reduce L-
CNV, but the 25 mg/kg dose had a marked effect (Fig. 9). This was qualitatively evident 
by OCT imaging on Day 7, and even more substantial on Day 14 (Fig. 9A). In addition, 
reduced fluorescein leakage was seen in lesions by fluorescein angiography at Day 14 
(Fig. 9B). Finally, L-CNV lesion volume assessed by ex vivo staining with agglutinin 
(Fig. 9C) and isolectin B4 (Supplemental Fig. 8), was reduced by 25 mg/kg APX2009 
approximately four-fold compared to vehicle (Fig. 9D).  
Discussion 
We have identified two new Ref-1 inhibitors, APX2009 and APX2014, and 
demonstrated antiangiogenic activity of these compounds. Moreover, we showed for the 
first time that systemic administration of Ref-1 inhibitors can attenuate L-CNV. As L-
CNV is a widely-used model that recapitulates the choroidal neovascularization 
underlying wet AMD, Ref-1 inhibition could find therapeutic utility for this indication. Our 
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in vitro data, and previous work (Jiang et al., 2011), suggest that Ref-1 inhibition also 
effectively blocks angiogenesis involving retinal endothelial cells. Thus, these inhibitors 
may also be useful for retinal neovascular diseases like ROP and PDR. 
The observed effects are likely attributable to inhibition of Ref-1 redox signaling, 
rather than DNA repair inhibition, as the compounds are specific for redox signaling 
inhibition. The molecularly distinct functional portions of Ref-1, redox and DNA repair, 
are completely independent. For example, mutations of the cysteine at position 65 
(C65A) of Ref-1/APE1 abrogate the redox function, but do not affect DNA repair 
function, and vice versa (McNeill and Wilson, 2007; Vasko et al., 2011). Moreover, Ref-
1 inhibitors such as APX3330 do not inhibit APE1 endonuclease activity. In fact, 
APX3330 and APX2009 can enhance APE1 repair activity in neurons (Kelley et al., 
2016), potentially contributing to a neuroprotective effect of these agents, which could 
offer an added benefit in the context of photoreceptor cell death in neovascular eye 
diseases.  
Given their anti-Ref-1 redox signaling activity, APX2009 and APX2014 likely 
exert their antiangiogenic effects by blocking the activation of transcription factors 
induced by Ref-1. This includes NF-κB as shown, and also possibly HIF-1α; both of 
these can regulate VEGF (Forsythe et al., 1996). In retinal pigment epithelial cells, 
APX3330 reduced both NF-κB and HIF-1α activity, with a concomitant reduction in 
VEGF expression (Li et al., 2014a; Li et al., 2014b), as we have shown here for 
APX2009 and APX2014. Additionally, APX3330 treatment of stroke in type one diabetes 
mellitus rats significantly decreased total vessel density and VEGF expression (Yan et 
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al., 2018). However, the full spectrum of transcription factors modulated by Ref-1 
inhibition in the context of ocular neovascularization remain to be determined. 
We did not observe obvious intraocular or systemic toxicity of the two 
compounds tested in vivo (APX3330 and APX2009), nor did we see apoptosis or 
substantial cell death in migration, tube formation, and choroidal sprouting assays. 
These findings are consistent with the excellent safety profile for APX3330 in humans 
(Shah et al., 2017). Nonetheless, ocular toxicity of the new compounds and intraocular 
pharmacokinetics remain to be thoroughly examined.  
A well-tolerated, systemic drug therapy has significant potential for treatment of 
neovascular eye diseases. The existing approved drugs are all biologics requiring 
intravitreal injection in the context of an ophthalmologist’s clinic. An orally bioavailable 
drug (as with APX3330) could be administered at home, potentially as a once daily pill. 
The tradeoff for such a therapy would be much more frequent dosing than that required 
for intravitreal injections (monthly or less), and more substantial systemic exposure than 
that seen with intravitreal therapies. But given the strong safety profile of Ref-1 
inhibitors, this approach is feasible. Moreover, patient and healthcare system costs 
might be significantly lower with such a therapy, as office visits and injection procedures 
could be reduced. 
In summary, we have explored Ref-1 inhibition as an ocular antiangiogenic 
therapy. We used two novel inhibitors of Ref-1 activity to demonstrate antiangiogenic 
effects in vitro, ex vivo, and in an animal model of CNV. The approach of targeting Ref-1 
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activity, and these small molecule inhibitors in particular, hold promise for development 
of therapies for treating diseases such as wet AMD, PDR, and ROP. 
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Legends for Figures  
Fig. 1. Synthesis and activity of Ref-1 inhibitors. (A) Synthetic scheme for APX2009 (6a) 
and APX2014 (6b). Structure of APX3330 (7) included for reference. Reagents and 
conditions: a, 2-iodo-3-hydroxy-1,4-naphthoquinone (iodolawsone, 1), 2-propylacrylic 
acid (2), K2CO3, Pd(OAc)2, argon, 100ºC, 1 hour, 74%; b, (COCl)2, DMF, DCM, RT 
overnight, 100%; c, DEA·HCl (APX2009) or CH3ONH2·HCl (APX2014), DIPA·HCl, RT, 
45 min, 62% and 71% respectively; d, NaOCH3/CH3OH, argon, 30 min, RT, 96% and 
86%, respectively. See Supplemental Methods for full synthetic details. (B) APX2009 
and APX2014 are more effective inhibitors of Ref-1-induced AP-1 DNA binding than 
APX3330 in an EMSA. Two separate gels from the same experiment are shown. The 
IC50 for redox EMSA inhibition was 25, 0.45 and 0.2 µM for APX3330, APX2009 and 
APX2014, respectively. These assays were performed multiple times with similar 
results. 
Fig. 2. Compounds APX2009 and APX2014 inhibit endothelial cell proliferation in 
HRECs and Rf/6a cells in vitro. Dose dependent effects of APX2009 (A) and APX2014 
(B) in human retinal endothelial cells (HRECs), and dose dependent effect of APX2009 
(C) and APX2014 (D) in Rf/6a choroidal endothelial cells. In vitro proliferation was 
measured using an alamarBlue assay. Median growth inhibition (GI50) values are 
indicated. Mean ± S.E.M., n = 3 per dose.   
Fig. 3. Compounds APX2009 and APX2014 inhibit S phase in HRECs. After treating 
HRECs with the indicated concentrations of APX2009 and APX2014, (A) EdU (red) and 
(C) Ki-67 (green) were detected and nuclei (blue) stained with DAPI; Scale bar = 100 
μm. (B) Quantification of EdU and (D) quantification of Ki-67 in HRECs. Mean ± S.E.M., 
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n = 3 fields per dose. **, p < 0.01; ****, p < 0.0001 compared to DMSO control (one-way 
ANOVA with Dunnett’s post hoc test). Representative data from three independent 
experiments. See Supplemental Figs. 1A & 2. 
Fig. 4. Compounds APX2009 and APX2014 inhibit endothelial cell migration in HRECs 
and Rf/6a cells in vitro. (A) Effect of APX2009 and APX2014 on cell migration in 
HRECs. A confluent monolayer of HRECs with various treatments (highest doses 
shown) was wounded and wound closure was monitored for 8 hours. (B) Quantitative 
analysis of cell migration shows that APX compounds significantly block the migration of 
HRECs. (C) Effect of APX2009 and APX2014 on cell migration in Rf/6a cells. A 
confluent monolayer of Rf/6a with various treatments (highest doses shown) was 
wounded and wound closure was monitored for 16 hours. (D) Quantitative analysis of 
cell migration shows that APX compounds significantly block the migration of Rf/6a 
cells. Mean ± S.E.M., n = 3 per dose. **, p < 0.01; ***, p < 0.001 compared to DMSO 
control (one-way ANOVA with Dunnett’s post hoc test). Representative data from three 
independent experiments. Scale bar = 500 μm. See Supplemental Figs. 4 & 5. 
Fig. 5. Compounds APX2009 and APX2014 inhibit endothelial tube formation in HRECs 
and Rf/6a cells in vitro. Representative images of tube formation on Matrigel by HRECs 
(A) and Rf/6a cells (C) in the presence of the indicated concentrations of APX 
compounds; Quantitative analysis of tube formation in HRECs (B) and Rf/6a cells (D) 
following APX2009 and APX2014 treatment. Tubular length was measured and 
represented as relative to DMSO control. Mean ± S.E.M., n  =  3 wells. **, p < 0.01; ***, p 
< 0.001 compared to DMSO control (one-way ANOVA with Dunnett’s post hoc test). 
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Representative data from three independent experiments. Scale bar = 500 μm. See 
Supplemental Figs. 6 & 7.  
Fig. 6. Compounds APX2009 and APX2014 inhibit TNF-α mediated NF-κB signaling 
and proangiogenic target gene mRNA expression. After treating HRECs with the 
indicated concentrations of APX2009 and APX2014, p65 (red) was detected by 
immunofluorescence and nuclei (blue) stained with DAPI; compounds dose-
dependently reduced p65 nuclear translocation as evidenced by decreased overlap 
between red and blue signals. BAY 11-7082 is a positive control NF-κB inhibitor. Scale 
bar = 100 μm. (B) VEGFA, (C) VCAM1, and (D) CCL20 mRNA expression levels in 
HRECs. APX2009 and APX2014 dose dependently inhibited levels of each transcript. 
Mean ± S.E.M., n  =  3 technical replicates. *, p < 0.05; **, p < 0.01; ***, p < 0.001 
compared to DMSO control (one-way ANOVA with Dunnett’s post hoc test). 
Representative data from three independent experiments. 
Fig. 7. Compounds APX2009 and APX2014 inhibit choroidal sprouting in a 
concentration-dependent manner. Representative phase contrast images of choroidal 
sprouts formed 48 hours after treatment with indicated concentrations of APX2009 (A) 
or APX2014 (C) or vehicle control (0.5% or 0.2% DMSO, respectively). Quantification of 
sprouting distance from the edge of the APX2009-treated (B) or APX2014-treated (D) 
choroidal tissue piece to the end of the sprouts averaged from four perpendicular 
directions using ImageJ software. Mean ± S.E.M., n = 4–6 choroids/per treatment; N = 
3–4 eyes.***, p < 0.001; ****, p < 0.0001 (ANOVA with Dunnett’s post hoc test). Scale 
bars = 500 μm. 
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Fig. 8. Systemic Ref-1 inhibition with APX3330 blocks neovascularization in the laser-
induced choroidal neovascularization (L-CNV) mouse model. (A) Representative optical 
coherence tomography (OCT) images obtained 7 days post-laser, showing CNV lesions 
in eyes of vehicle (left) and 50 mg/kg i.p. APX3330 treated animals (right). (B) 
Representative images from confocal microscopy for agglutinin-stained CNV lesions 14 
days post-laser treatment. (C) Quantification of CNV lesion vascular volumes from Z-
stack images at day 14 using ImageJ software. Mean ± S.E.M., n = 7–9 eyes/treatment. 
* p < 0.05 (unpaired Student’s t-test). Scale bars = 100 μm. GCL, ganglion cell layer; 
INL, inner nuclear layer; ONL, outer nuclear layer. 
Fig. 9. Intraperitoneal APX2009 inhibits choroidal neovascularization in the L-CNV 
mouse model. (A) Representative OCT images obtained 7 and 14 days post-laser, 
showing CNV lesions of untouched control, vehicle, 12.5 mg/kg  and 25 mg/kg 
APX2009 compound i.p. injected twice daily until 14 days post-laser treatment. (B) 
Fluorescein angiography (FA) of CNV showing the vascular leakage suppression by 
APX2009. (C) Representative images from confocal microscopy for agglutinin-stained 
CNV lesions 14 days post-laser treatment. (D) Quantification of CNV lesion vascular 
volumes from Z-stack images at day 14 using ImageJ software. Mean ± S.E.M., n = 8–
10 eyes/treatment. ns, non-significant; ***, p < 0.001 compared to DMSO control (one-
way ANOVA with Tukey’s post hoc test). Scale bars = 100 μm. GCL, ganglion cell layer; 
INL, inner nuclear layer; ONL, outer nuclear layer. See also Supplemental Fig. 5. 
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